Clinical burden and work productivity impairment in moderate-to-severe atopic dermatitis patients in the United States

被引：0
|
作者：
Feldman, Steven R. [1 ]
Guerin, Annie [2 ]
Gauthier-Loiselle, Marjolaine [2 ]
Claxton, Ami J. [3 ]
Hazra, Nisha C. [4 ]
Meng, Yan [4 ]
Gallant, Kirsten [4 ]
Balu, Sanjeev [3 ]
机构：
[1] Wake Forest Univ, Sch Med, Winston Salem, NC USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] LEO Pharma, Madison, NJ USA
[4] Anal Grp Inc, London, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
atopic dermatitis; work productivity and activity impairment; disease burden; comorbidity;
D O I：
10.1093/bjd/ljad498.047
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
547
引用
收藏
页码：II45 / II46
页数：2
相关论文
共 50 条
  • [41] Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study
    Mihara, Ryosuke
    Kabashima, Kenji
    Furue, Masutaka
    Nakano, Miwa
    Ruzicka, Thomas
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 662 - 671
  • [42] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT AMONG PATIENTS WITH ATOPIC DERMATITIS IN TAIWAN
    Lin, Y. C.
    Chu, C. Y.
    Cho, Y. T.
    Lee, C. H.
    Tsai, C. T.
    Tang, C. H.
    VALUE IN HEALTH, 2019, 22 : S376 - S376
  • [43] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Okragly, Angela
    Sun, Zhe
    Mena, Laura Rebeca
    Hahn, Nathan
    Nickoloff, Brian J.
    Siu, Kimberly
    Gallo, Gaia
    Wolf, Eric
    Eyerich, Kilian
    Aparici, Monica
    Benschop, Robert J.
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II4 - II5
  • [44] Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients
    Dal Bello, Giacomo
    Maurelli, Martina
    Schena, Donatella
    Girolomoni, Giampiero
    Gisondi, Paolo
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [45] Lebrikizumab reduces systemic inflammation in serum of patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, E.
    Okragly, A.
    Sun, Z.
    Mena, L. R.
    Hahn, N.
    Nickoloff, B. J.
    Siu, K.
    Gallo, G.
    Wolf, E.
    Eyerich, K.
    Aparici, M.
    Benschop, R. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364
  • [46] DUPILUMAB TREATMENT RAPIDLY IMPROVES ITCH IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Silverberg, J.
    Chao, J.
    Eckert, L.
    Chen, Z.
    Ardeleanu, M.
    Shumel, B.
    Plaum, S.
    Graham, N.
    Pirozzi, G.
    Gadkari, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S95 - S95
  • [47] Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis
    Marcant, P.
    Balaye, P.
    Merhi, R.
    Jendoubi, F.
    Nosbaum, A.
    Raison-Peyron, N.
    Du-Thanh, A.
    Lasek, A.
    Ferrier le Bouedec, M. -C.
    Tetart, F.
    Valois, A.
    Barbarot, S.
    Soria, A.
    Jachiet, M.
    Staumont-Salle, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (06) : E394 - E396
  • [48] BUDGET IMPACT ANALYSIS OF TRALOKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS IN THE UK
    Chalmers, K.
    Sawyer, L.
    Sohrt, A.
    Robinson, S.
    Ryttig, L.
    Rinciog, C.
    VALUE IN HEALTH, 2022, 25 (12) : S124 - S124
  • [49] The patient burden of atopic dermatitis: insights from a dupilumab phase 2 clinical trial in adults with moderate-to-severe disease
    Mastey, V.
    Simpson, E.
    Bieber, T.
    Eckert, L.
    Wu, R.
    Ardeleanu, M.
    Graham, N.
    Pirozzi, G.
    Sutherland, E. R.
    EXPERIMENTAL DERMATOLOGY, 2014, 23 : 4 - 4
  • [50] Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies
    Schmid-Grendelmeier, Peter
    Gooderham, Melinda J.
    Hartmann, Karin
    Konstantinou, George N.
    Fellmann, Marc
    Koulias, Christopher
    Clibborn, Claire
    Biswas, Pinaki
    Brunner, Patrick M.
    ALLERGY, 2024, 79 (01) : 174 - 183
12345